CS-20AT04(CS-20AT04) - 在研适应症：自身免疫性血细胞减少症，狼疮性肾炎_专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名

+ [1]

靶点-

作用机制

细胞替代物

治疗领域

免疫系统疾病血液及淋巴系统疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

自身免疫性血细胞减少症狼疮性肾炎

非在研适应症-

原研机构

CORESTEMCHEMON, Inc.

在研机构

CORESTEMCHEMON, Inc.

非在研机构

Hanyang University

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 CS-20AT04 相关的临床试验

NCT04835883 / Recruiting临床2期IIT

Open-label, Single-arm, 24-week Investigator Study to Evaluate the Efficacy and Safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) Administered in Patients With Lupus Nephritis or Lupus Cytopenia

This is an open-label, one-arm single-center phase Ⅱa study exploring the efficacy and safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) in two subpopulation group of systemic lupus erythematosus patients - lupus nephritis and lupus cytopenia.

开始日期2019-09-26

申办/合作机构

South Korea Ministry of Health & Welfare

[+1]

NCT04522505 / CompletedN/A

Long-term Follow-up for Safety Evaluation of Subjects Who Participated in the Phase 1 Clinical Trial of CS20AT04(CS20AT04-LN101) in Lupus Nephritis

This observation study is planned to evaluate the safety and efficacy of the subjects who received CS20AT04 in the phase 1 clinical trial.
If the subjects who participated in the phase 1 clinical trial voluntarily agree to participate in this observation study, visit 1 and visit 2 will be conducted every 3 months according to the clinical trial protocol until 6 months after administration of CS20AT04 in the phase 1 clinical trial. And Visit 3 after 6 months, Visit 4
Visit 7 will be conducted every 12 months. During each visit, subjects are assessed for the efficacy and occurrence of adverse events.

开始日期2017-11-29

申办/合作机构

CORESTEMCHEMON, Inc.

[+1]

100 项与 CS-20AT04 相关的临床结果

登录后查看更多信息

100 项与 CS-20AT04 相关的转化医学

登录后查看更多信息

100 项与 CS-20AT04 相关的专利（医药）

登录后查看更多信息

100 项与 CS-20AT04 相关的药物交易

登录后查看更多信息